Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Oxazolidinones: a new class of antibacterials.

Zurenko GE, Gibson JK, Shinabarger DL, Aristoff PA, Ford CW, Tarpley WG.

Curr Opin Pharmacol. 2001 Oct;1(5):470-6. Review.

PMID:
11764772
2.
3.

Discovery and development of the BHAP nonnucleoside reverse transcriptase inhibitor delavirdine mesylate.

Adams WJ, Aristoff PA, Jensen RK, Morozowich W, Romero DL, Schinzer WC, Tarpley WG, Thomas RC.

Pharm Biotechnol. 1998;11:285-312. Review. No abstract available.

PMID:
9760685
4.

Pyrimidine thioethers: a novel class of HIV-1 reverse transcriptase inhibitors with activity against BHAP-resistant HIV.

Nugent RA, Schlachter ST, Murphy MJ, Cleek GJ, Poel TJ, Wishka DG, Graber DR, Yagi Y, Keiser BJ, Olmsted RA, Kopta LA, Swaney SM, Poppe SM, Morris J, Tarpley WG, Thomas RC.

J Med Chem. 1998 Sep 24;41(20):3793-803.

PMID:
9748354
5.

Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor.

Poppe SM, Slade DE, Chong KT, Hinshaw RR, Pagano PJ, Markowitz M, Ho DD, Mo H, Gorman RR 3rd, Dueweke TJ, Thaisrivongs S, Tarpley WG.

Antimicrob Agents Chemother. 1997 May;41(5):1058-63.

6.

Structure-based design of HIV protease inhibitors: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors.

Thaisrivongs S, Skulnick HI, Turner SR, Strohbach JW, Tommasi RA, Johnson PD, Aristoff PA, Judge TM, Gammill RB, Morris JK, Romines KR, Chrusciel RA, Hinshaw RR, Chong KT, Tarpley WG, Poppe SM, Slade DE, Lynn JC, Horng MM, Tomich PK, Seest EP, Dolak LA, Howe WJ, Howard GM, Watenpaugh KD, et al.

J Med Chem. 1996 Oct 25;39(22):4349-53. No abstract available.

PMID:
8893827
7.

Targeting delavirdine/atevirdine resistant HIV-1: identification of (alkylamino)piperidine-containing bis(heteroaryl)piperazines as broad spectrum HIV-1 reverse transcriptase inhibitors.

Romero DL, Olmsted RA, Poel TJ, Morge RA, Biles C, Keiser BJ, Kopta LA, Friis JM, Hosley JD, Stefanski KJ, Wishka DG, Evans DB, Morris J, Stehle RG, Sharma SK, Yagi Y, Voorman RL, Adams WJ, Tarpley WG, Thomas RC.

J Med Chem. 1996 Sep 13;39(19):3769-89.

PMID:
8809165
8.

A drug resistance mutation in the inhibitor binding pocket of human immunodeficiency virus type 1 reverse transcriptase impairs DNA synthesis and RNA degradation.

Fan N, Rank KB, Slade DE, Poppe SM, Evans DB, Kopta LA, Olmsted RA, Thomas RC, Tarpley WG, Sharma SK.

Biochemistry. 1996 Jul 30;35(30):9737-45.

PMID:
8703945
9.
10.

The benzylthio-pyrimidine U-31,355, a potent inhibitor of HIV-1 reverse transcriptase.

Althaus IW, Chou KC, Lemay RJ, Franks KM, Deibel MR, Kezdy FJ, Resnick L, Busso ME, So AG, Downey KM, Romero DL, Thomas RC, Aristoff PA, Tarpley WG, Reusser F.

Biochem Pharmacol. 1996 Mar 22;51(6):743-50.

PMID:
8602869
11.

Characterization of the p68/p58 heterodimer of human immunodeficiency virus type 2 reverse transcriptase.

Fan N, Rank KB, Poppe SM, Tarpley WG, Sharma SK.

Biochemistry. 1996 Feb 13;35(6):1911-7.

PMID:
8639674
12.

Validation of a quantitative RNA PCR assay for HIV-1 in human plasma.

Wathen LK, Crampton DJ, Patel RK, Nuorala KW, Poppe SM, Dueweke TJ, Re' KA, Krieger KS, Tarpley WG.

J Clin Lab Anal. 1996;10(5):262-8.

PMID:
8887005
14.

The differential processing of homodimers of reverse transcriptases from human immunodeficiency viruses type 1 and 2 is a consequence of the distinct specificities of the viral proteases.

Fan N, Rank KB, Leone JW, Heinrikson RL, Bannow CA, Smith CW, Evans DB, Poppe SM, Tarpley WG, Rothrock DJ, et al.

J Biol Chem. 1995 Jun 2;270(22):13573-9.

16.
17.

Kinetic studies with the non-nucleoside human immunodeficiency virus type-1 reverse transcriptase inhibitor U-90152E.

Althaus IW, Chou JJ, Gonzales AJ, Deibel MR, Chou KC, Kezdy FJ, Romero DL, Thomas RC, Aristoff PA, Tarpley WG, et al.

Biochem Pharmacol. 1994 Jun 1;47(11):2017-28.

PMID:
7516658
18.

Inhibition of the protease of human immunodeficiency virus blocks replication and infectivity of the virus in chronically infected macrophages.

Perno CF, Bergamini A, Pesce CD, Milanese G, Capozzi M, Aquaro S, Thaisrivongs S, Tarpley WG, Zon G, D'Agostini C, et al.

J Infect Dis. 1993 Nov;168(5):1148-56.

PMID:
8228348
20.
21.

Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection.

Bukrinsky MI, Sharova N, McDonald TL, Pushkarskaya T, Tarpley WG, Stevenson M.

Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):6125-9.

22.

A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors.

Dueweke TJ, Pushkarskaya T, Poppe SM, Swaney SM, Zhao JQ, Chen IS, Stevenson M, Tarpley WG.

Proc Natl Acad Sci U S A. 1993 May 15;90(10):4713-7.

24.

Inhibitors of the protease from human immunodeficiency virus: synthesis, enzyme inhibition, and antiviral activity of a series of compounds containing the dihydroxyethylene transition-state isostere.

Thaisrivongs S, Turner SR, Strohbach JW, TenBrink RE, Tarpley WG, McQuade TJ, Heinrikson RL, Tomasselli AG, Hui JO, Howe WJ.

J Med Chem. 1993 Apr 16;36(8):941-52.

PMID:
8478908
25.

Steady-state kinetic studies with the non-nucleoside HIV-1 reverse transcriptase inhibitor U-87201E.

Althaus IW, Chou JJ, Gonzales AJ, Deibel MR, Chou KC, Kezdy FJ, Romero DL, Aristoff PA, Tarpley WG, Reusser F.

J Biol Chem. 1993 Mar 25;268(9):6119-24.

26.

Prevention of the spread of HIV-1 infection with nonnucleoside reverse transcriptase inhibitors.

Vasudevachari MB, Battista C, Lane HC, Psallidopoulos MC, Zhao B, Cook J, Palmer JR, Romero DL, Tarpley WG, Salzman NP.

Virology. 1992 Sep;190(1):269-77.

PMID:
1382341
27.

Purification of an active monomeric recombinant HIV-1 trans-activator.

Waszak GA, Hasler JM, McQuade TJ, Tarpley WG, Deibel MR Jr.

Protein Expr Purif. 1992 Apr;3(2):126-33.

PMID:
1422216
28.

Resolution of microheterogeneity associated with recombinant HIV-1 heterodimeric reverse transcriptase.

Chattopadhyay D, Einspahr HM, Brunner DP, Strakalaitis NA, Tarpley WG, Deibel MR Jr.

Protein Expr Purif. 1992 Apr;3(2):151-9.

PMID:
1384859
30.

The binding of a novel bisheteroarylpiperazine mediates inhibition of human immunodeficiency virus type 1 reverse transcriptase.

Dueweke TJ, Kézdy FJ, Waszak GA, Deibel MR Jr, Tarpley WG.

J Biol Chem. 1992 Jan 5;267(1):27-30.

31.

A recombinant ribonuclease H domain of HIV-1 reverse transcriptase that is enzymatically active.

Evans DB, Brawn K, Deibel MR Jr, Tarpley WG, Sharma SK.

J Biol Chem. 1991 Nov 5;266(31):20583-5.

33.

Inhibitors of the protease from human immunodeficiency virus: design and modeling of a compound containing a dihydroxyethylene isostere insert with high binding affinity and effective antiviral activity.

Thaisrivongs S, Tomasselli AG, Moon JB, Hui J, McQuade TJ, Turner SR, Strohbach JW, Howe WJ, Tarpley WG, Heinrikson RL.

J Med Chem. 1991 Aug;34(8):2344-56.

PMID:
1875334
34.

Metal affinity chromatography of recombinant HIV-1 reverse transcriptase containing a human renin cleavable metal binding domain.

Sharma SK, Evans DB, Vosters AF, McQuade TJ, Tarpley WG.

Biotechnol Appl Biochem. 1991 Aug;14(1):69-81.

PMID:
1716913
35.

Expression and characterization of chimeric rDNA proteins engineered for purification and enzymatic cleavage.

Evans DB, Tarpley WG, Sharma SK.

Protein Expr Purif. 1991 Apr-Jun;2(2-3):205-13.

PMID:
1726560
36.

Functional characterization of RNA-dependent DNA polymerase and RNase H activities of a recombinant HIV reverse transcriptase.

Tan CK, Zhang J, Li ZY, Tarpley WG, Downey KM, So AG.

Biochemistry. 1991 Mar 12;30(10):2651-5.

PMID:
1705816
37.

An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection.

Ashorn P, McQuade TJ, Thaisrivongs S, Tomasselli AG, Tarpley WG, Moss B.

Proc Natl Acad Sci U S A. 1990 Oct;87(19):7472-6.

38.

P388 leukaemia cells resistant to the anthracycline menogaril lack multidrug resistant phenotype.

Badiner GJ, Moy BC, Smith KS, Tarpley WG, Groppi VE, Bhuyan BK.

Br J Cancer. 1990 Sep;62(3):378-84.

39.

Escherichia coli expression, purification, and biological activity of a truncated soluble CD4.

Garlick RL, Kirschner RJ, Eckenrode FM, Tarpley WG, Tomich CS.

AIDS Res Hum Retroviruses. 1990 Apr;6(4):465-79.

PMID:
2187501
40.

Denaturation/refolding of purified recombinant HIV reverse transcriptase yields monomeric enzyme with high enzymatic activity.

Deibel MR Jr, McQuade TJ, Brunner DP, Tarpley WG.

AIDS Res Hum Retroviruses. 1990 Mar;6(3):329-40.

PMID:
1692723
41.

A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation.

McQuade TJ, Tomasselli AG, Liu L, Karacostas V, Moss B, Sawyer TK, Heinrikson RL, Tarpley WG.

Science. 1990 Jan 26;247(4941):454-6.

PMID:
2405486
42.

A rapid, quantitative bioassay based on the human immunodeficiency virus trans-activator.

Hasler JM, Weighous TF, Pitts TW, Evans DB, Sharma SK, Tarpley WG.

AIDS Res Hum Retroviruses. 1989 Oct;5(5):507-16.

PMID:
2590554
43.

A rapid solution immunoassay to quantify binding of the human immunodeficiency virus envelope glycoprotein to soluble CD4.

McQuade TJ, Pitts TW, Tarpley WG.

Biochem Biophys Res Commun. 1989 Aug 30;163(1):172-6.

PMID:
2549987
44.

Regulation of Na+-H+ exchange in normal NIH-3T3 cells and in NIH-3T3 cells expressing the ras oncogene.

Owen NE, Knapik J, Strebel F, Tarpley WG, Gorman RR.

Am J Physiol. 1989 Apr;256(4 Pt 1):C756-63.

PMID:
2539724
45.

NIH-3T3 cells transformed by the EJ-ras oncogene exhibit reduced platelet-derived growth factor-mediated Ca2+ mobilization.

Benjamin CW, Connor JA, Tarpley WG, Gorman RR.

Proc Natl Acad Sci U S A. 1988 Jun;85(12):4345-9.

46.
47.
48.
49.

Inhibition of adenylate cyclase and phospholipase A2/C in NIH-3T3 cells expressing the EJ-ras oncogene.

Gorman RR, Benjamin CW, Tarpley WG.

Adv Prostaglandin Thromboxane Leukot Res. 1987;17B:963-8. No abstract available.

PMID:
2960212
50.

Supplemental Content

Loading ...
Support Center